Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
Cytokinetics, incorporated (Nasdaq: CYTK), will present data on CK-274, a cardiac myosin inhibitor aimed at treating hypertrophic cardiomyopathies (HCM), at the American Chemical Society Spring 2021 Virtual Meeting from April 5 to April 30, 2021. The presentation titled 'Discovery of CK-274' is scheduled for April 9, 2021, featuring Dr. Grace Chuang. The company is advancing several clinical trials, including the REDWOOD-HCM Phase 2 study for CK-274 and the METEORIC-HF Phase 3 study for omecamtiv mecarbil, after positive results from previous trials.
- Data on CK-274 will be presented, highlighting advancements in cardiac myosin inhibitors.
- Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil after positive Phase 3 results.
- None.
SOUTH SAN FRANCISCO, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring 2021 Virtual Meeting, taking place online from April 5, 2021 to April 30, 2021.
Session Title: First Time Disclosures
Presentation Title: Discovery of CK-274: A novel, small molecule, cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathies (HCM)
Presenter: Grace (Chihyuan) Chuang, Ph.D., Director, Medicinal Chemistry, Cytokinetics
Date: Friday, April 9, 2021
Time: 11:05 AM – 11:45 AM PT
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is preparing for the potential advancement of reldesemtiv to a Phase 3 clinical trial in ALS. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities; the timing of enrollment of patients in Cytokinetics’ and its partners’ clinical trials; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics’ drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Cytokinetics’ partners decisions with respect to research and development activities; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics’ collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-3060
FAQ
What is CK-274, and what is its purpose?
When will the data on CK-274 be presented?
What are the next steps for Cytokinetics regarding CK-274?
What is the significance of the GALACTIC-HF trial for Cytokinetics?
